search
Back to results

A Randomised Feasibility Trial With Internet Based Self-help Therapy (IBT)

Primary Purpose

Anxiety

Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
FearFighter
Sponsored by
Mental Health Services in the Capital Region, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety focused on measuring anxiety, behaviour therapy, computer assisted therapy, psychotherapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 or older.
  • Specific phobia, panic disorder, agoraphobia or social phobia is the primary diagnosis according to the DSM-IV
  • Written informed consent.

Exclusion Criteria:

  • Acute suicidal risk.
  • Ongoing episode of bipolar disorder or psychosis.
  • Receive concurrent psychological treatment for an anxiety disorder
  • Considered unable to attend IBT sessions as planned (due to vacation, work/study placement, sickness or similar occurrences).
  • Lack of informed consent.

Sites / Locations

  • Psychotherapy Center Stolpegård, Mental Health Services in the Capital Region of Denmark

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

FearFighter

Control group

Arm Description

The experimental group will use the program FearFighter™.

The control group receive no intervention for nine weeks.

Outcomes

Primary Outcome Measures

Fractions of participants that are eligible and can be randomised
We will determine the fraction of potential participants as the number of eligible persons compared to the number of randomised persons. Here, we consider eligible participants' to be persons who fulfill the inclusion criteria. Exclusion criteria and informed consent is not included in this definition of eligibility.
Fraction of participants randomised to the experimental group that will comply with the experimental intervention
We will determine the fraction of participants randomised to the experimental group that will comply with the experimental intervention, defined as completing at least 6 of 9 FearFighter™ sessions during the intervention
Proportion of participants who fulfil the diagnostic criteria for an anxiety disorder at the end of the intervention measured with 'Mini International Neuropsychiatric Interview' (M.I.N.I.)
Participants are diagnostic assessed with the 'Mini International Neuropsychiatric Interview' (M.I.N.I.), a short structured interview for the most important psychiatric axis 1 diagnoses in DSM-IV and in ICD-10.

Secondary Outcome Measures

Symptoms: Beck Anxiety Inventory (BAI)
Beck Anxiety Inventory (BAI) is a 21-items general questionnaire for anxiety symptoms during the last 14 days.
Symptoms: Symptom check list-90R (SCL-90R)
Symptom check list-90R (SCL-90R) is a 90-item questionnaire measuring psychological distress and psychopathology (35). Within SCL-90R we use: Global severity index (GSI); Interpersonal sensitivity subscale; Anxiety subscale; and Phobic anxiety subscale.
Functionality: Sheehan Disability Scale (SDS)
Sheehan Disability Scale (SDS). We assess: Occupational function; Social function; and Family function.
Quality of life: WHO Well-Being Index
WHO Well-Being Index.,We assess the quality of life.
Serious adverse events (SAE)
Serious adverse events, defined as any adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. Other adverse events, defined as any undesirable medical event occurring to a participant during a clinical trial, which does not necessarily have a causal relationship with the intervention.

Full Information

First Posted
July 1, 2015
Last Updated
October 11, 2016
Sponsor
Mental Health Services in the Capital Region, Denmark
Collaborators
Copenhagen Trial Unit, Center for Clinical Intervention Research, TrygFonden, Denmark, Student Counselling Service, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT02499055
Brief Title
A Randomised Feasibility Trial With Internet Based Self-help Therapy
Acronym
IBT
Official Title
Internet Based Self-help Therapy With FearFighter™ Versus no Intervention for Anxiety Disorders in Adult Persons: a Randomised Feasibility Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Unknown status
Study Start Date
August 2015 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mental Health Services in the Capital Region, Denmark
Collaborators
Copenhagen Trial Unit, Center for Clinical Intervention Research, TrygFonden, Denmark, Student Counselling Service, Denmark

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background. In Denmark, about 350,000 persons suffer from anxiety. Public health-care services plan to implement internet based self-help psychotherapy (IBT) to be an important alternative and supplement to ordinary face-to-face therapy. Meta-analyses indicate that the effect of IBT for anxiety disorders seems better than no intervention, and in some instances equal to 'usual therapy'. But studies have been characterised by small sample sizes, high risk for bias, including high dropout. Objective. The objective of this pilot trial is to assess the feasibility of conducting a larger confirmatory trial investigating the benefits and harms of an internet-based self-help therapy program, FearFighter™, compared with no intervention for persons with an anxiety disorder. Design. An investigator-initiated feasibility randomised clinical trial investigating internet-based therapy with FearFighter™ compared with no intervention for persons with an anxiety disorder. We will include 64 participants. Eligibility criteria. Inclusion criteria: age 18 or older; specific phobia, panic disorder, agoraphobia, or social phobia is the primary diagnosis according to the DSM-IV; and informed consent. Exclusion criteria: suicidal risk; ongoing episode of bipolar disorder or psychosis; concurrent psychological treatment for the anxiety disorder; unable to attend the intervention; or lack of informed consent. Intervention. The intervention group will use the program FearFighter™, a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. The control group receive no intervention for nine weeks. Outcomes. Feasibility outcomes are the fraction that are eligible, the fraction that are randomised, and the compliance in the intervention group. Clinical exploratory outcomes are: remission, Beck Anxiety Inventory, Symptom Check List-90R, WHO Well-Being Index, Sheehan Disability Scale, serious adverse events, and behaviour log from FearFighter. Time schedule. Participants will be included in the trial from July 2015. Results are expected in February 2016.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety
Keywords
anxiety, behaviour therapy, computer assisted therapy, psychotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FearFighter
Arm Type
Experimental
Arm Description
The experimental group will use the program FearFighter™.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
The control group receive no intervention for nine weeks.
Intervention Type
Behavioral
Intervention Name(s)
FearFighter
Other Intervention Name(s)
Internet based therapy, Computer assisted therapy
Intervention Description
FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
Primary Outcome Measure Information:
Title
Fractions of participants that are eligible and can be randomised
Description
We will determine the fraction of potential participants as the number of eligible persons compared to the number of randomised persons. Here, we consider eligible participants' to be persons who fulfill the inclusion criteria. Exclusion criteria and informed consent is not included in this definition of eligibility.
Time Frame
up to week 10
Title
Fraction of participants randomised to the experimental group that will comply with the experimental intervention
Description
We will determine the fraction of participants randomised to the experimental group that will comply with the experimental intervention, defined as completing at least 6 of 9 FearFighter™ sessions during the intervention
Time Frame
up to week 10
Title
Proportion of participants who fulfil the diagnostic criteria for an anxiety disorder at the end of the intervention measured with 'Mini International Neuropsychiatric Interview' (M.I.N.I.)
Description
Participants are diagnostic assessed with the 'Mini International Neuropsychiatric Interview' (M.I.N.I.), a short structured interview for the most important psychiatric axis 1 diagnoses in DSM-IV and in ICD-10.
Time Frame
up to 37 weeks after start of intervention
Secondary Outcome Measure Information:
Title
Symptoms: Beck Anxiety Inventory (BAI)
Description
Beck Anxiety Inventory (BAI) is a 21-items general questionnaire for anxiety symptoms during the last 14 days.
Time Frame
Baseline, 10 weeks and 37 weeks after start of intervention
Title
Symptoms: Symptom check list-90R (SCL-90R)
Description
Symptom check list-90R (SCL-90R) is a 90-item questionnaire measuring psychological distress and psychopathology (35). Within SCL-90R we use: Global severity index (GSI); Interpersonal sensitivity subscale; Anxiety subscale; and Phobic anxiety subscale.
Time Frame
Baseline, 10 weeks and 37 weeks after start of intervention
Title
Functionality: Sheehan Disability Scale (SDS)
Description
Sheehan Disability Scale (SDS). We assess: Occupational function; Social function; and Family function.
Time Frame
Baseline, 10 weeks and 37 weeks after start of intervention
Title
Quality of life: WHO Well-Being Index
Description
WHO Well-Being Index.,We assess the quality of life.
Time Frame
Baseline, 10 weeks and 37 weeks after start of intervention
Title
Serious adverse events (SAE)
Description
Serious adverse events, defined as any adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. Other adverse events, defined as any undesirable medical event occurring to a participant during a clinical trial, which does not necessarily have a causal relationship with the intervention.
Time Frame
SAE will be registrered throughout the intervention from week 0 to week 10
Other Pre-specified Outcome Measures:
Title
Behaviour log from FearFighter
Description
Registration of the number of times the participant log on FearFighter.
Time Frame
Behaviour log will be registrered throughout the intervention from week 0 to week 10

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 or older. Specific phobia, panic disorder, agoraphobia or social phobia is the primary diagnosis according to the DSM-IV Written informed consent. Exclusion Criteria: Acute suicidal risk. Ongoing episode of bipolar disorder or psychosis. Receive concurrent psychological treatment for an anxiety disorder Considered unable to attend IBT sessions as planned (due to vacation, work/study placement, sickness or similar occurrences). Lack of informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marianne Lau, MD
Organizational Affiliation
Stolpegaard Psychotherapy Centre. Mental Health Services in the Capital Region of Denmark.
Official's Role
Study Director
Facility Information:
Facility Name
Psychotherapy Center Stolpegård, Mental Health Services in the Capital Region of Denmark
City
Gentofte
State/Province
Capital Region
ZIP/Postal Code
2820
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
32401099
Citation
Fenger M, Lindschou J, Gluud C, Winkel P, Jorgensen L, Dybkjaer JH, Lau M. Internet-based therapy with FearFighter for anxiety disorders: a randomised clinical trial. Nord J Psychiatry. 2020 Oct;74(7):518-524. doi: 10.1080/08039488.2020.1755363. Epub 2020 May 13.
Results Reference
derived
PubMed Identifier
27793181
Citation
Fenger M, Lindschou J, Gluud C, Winkel P, Jorgensen L, Kruse-Blinkenberg S, Lau M. Internet-based self-help therapy with FearFighter versus no intervention for anxiety disorders in adults: study protocol for a randomised controlled trial. Trials. 2016 Oct 28;17(1):525. doi: 10.1186/s13063-016-1619-3.
Results Reference
derived

Learn more about this trial

A Randomised Feasibility Trial With Internet Based Self-help Therapy

We'll reach out to this number within 24 hrs